Timothy A Yap, MD, PhD of MD Anderson Cancer Center @MDAndersonNews discusses AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors.
Read here: https://meetinglibrary.asco.org/record/187808/abstract
Advertisement